Hugel, the South Korean maker of botulinum toxin and hyaluronic acid fillers, has set a target of 1 trillion won in annual sales within three years, Seoul Economic Daily reports.

The company announced the goal as part of a mid-term growth roadmap. The headline figure marks an ambitious step up for a firm that has built its business on injectable aesthetics products sold in both domestic and export markets.

What do we know about the plan?

The source report gives the essentials:

• Target: 1 trillion won in sales
• Timeframe: within three years
• Company: Hugel, a Korean pharmaceutical and aesthetics manufacturer

The Seoul Economic Daily item, as carried in syndication, does not break the target down by product line, region or fiscal year. It frames the goal as a corporate milestone rather than a trial or regulatory announcement.

Why the number matters

A 1 trillion won revenue goal signals scale ambitions in a global injectables market where Korean manufacturers have gained share on the strength of lower-cost botulinum toxin alternatives. For dermatology practices, Hugel's growth trajectory points to continued expansion of its product availability across aesthetic clinics in Asia and export markets.

What the report does not specify is which segments — toxin, filler, or skincare — are expected to drive the largest share of growth, nor whether the target rests on organic sales, new market approvals, or acquisition.

What comes next

Hugel has given itself three years to reach the 1 trillion won mark; the pace of its regulatory clearances and export expansion over the coming quarters will show whether the target is a stretch or a baseline.